A Research Guide for
Families Facing PUS7 Deficiency

Understanding that PUS7 deficiency is caused by loss of a single enzyme opens the door to gene therapy. If scientists can deliver a working copy of the PUS7 gene to cells — particularly brain cells — those cells could produce the missing enzyme and restore normal tRNA modification. This is the same basic strategy used in Zolgensma (for spinal muscular atrophy) and other approved gene therapies. PUS7 is a small gene that fits easily within the carrying capacity of adeno-associated virus (AAV) vectors, making it a technically favorable candidate.

For most families, a PUS7 diagnosis arrives at the end of what doctors call a "diagnostic odyssey" — often years of noticing that something was different about your child's development, of appointments and tests that came back normal or inconclusive, of possible labels that did not quite fit, and of living with uncertainty. Receiving a specific genetic answer can bring a complicated mix of feelings, and all of them are normal. There is often relief — finally a name, an explanation, and proof that you were right to keep pushing; this was never caused by anything you did. There can also be grief, because a definite diagnosis can close the door on hopes you had been holding, and fear about the future. Many parents describe both at once. A few things help in this period. Know that the diagnosis does not change who your child is — they are the same beloved child as the day before — but it does change what help is available, connecting you to the right specialists, services, and (eventually) other families. Give yourself permission to feel whatever you feel without judging it, and to take in the information gradually; you do not have to understand or decide everything at once. And recognize the diagnosis for what it also is: not the end of a search, but the beginning of a clearer path forward.

PUS7 deficiency is not just rare but ultra-rare — only around fifteen people in the world have been identified with it so far. Learning this can feel frightening and isolating, so it helps to understand what it does and does not mean. It does not mean your child cannot be helped: the day-to-day care that makes the biggest difference — speech and communication support, therapies, managing seizures or hearing or feeding, and steady developmental help — is well-established care that does not depend on the condition being common. What ultra-rare does mean is mostly practical. You may meet doctors who have never heard of PUS7, which makes you, the parent, an essential source of information about your own child (more on that elsewhere in this guide). There is not yet a large community of other PUS7 families or a dedicated foundation, so connection often comes through broader rare-disease and intellectual-disability communities, and through the research programs that study undiagnosed and ultra-rare conditions. And research moves more slowly when a disease affects so few people — not because the science is impossible, but because it takes deliberate effort to organize. None of this changes the love and the ordinary childhood your child deserves. Knowing the practical realities of ultra-rare simply helps you find the right supports faster and feel less alone in doing it.

• Can you explain exactly which PUS7 mutation my child has and what it means?
• Have you seen PUS7 deficiency before, and if not, are you willing to learn about it with us?
• Which specialists should be on my child’s care team?
• Should we contact the NIH Undiagnosed Diseases Program or a genetics research center?
• Is there a natural history study or patient registry we should join?
• What early intervention services should we start right now?

• Whole Exome Sequencing (WES): This is the most common way PUS7 deficiency has been discovered. WES reads the protein-coding portions of all ~20,000 genes simultaneously. It is increasingly available through genetics clinics and can be covered by insurance when there is a clinical indication (such as unexplained intellectual disability). Results typically take 8–16 weeks.
• Whole Genome Sequencing (WGS): Reads the entire DNA sequence, including non-coding regions. More comprehensive than WES but more expensive. Some academic centers and research programs offer WGS.
• Gene Panel Testing: Some laboratories offer panels testing hundreds of genes associated with intellectual disability. PUS7 may or may not be included on all panels — ask the laboratory specifically.
• Chromosomal Microarray (CMA): This test detects large deletions and duplications but will not identify the point mutations that cause most PUS7 deficiency cases. A normal CMA result does not rule out PUS7 deficiency.

Important: If your child has unexplained intellectual disability with short stature and microcephaly, and standard genetic tests (karyotype, microarray) have been normal, ask about whole exome or whole genome sequencing. Many PUS7 families waited years before receiving a diagnosis because these newer tests were not performed initially.

When WES or WGS identifies a PUS7 variant, several steps confirm the diagnosis:

• Parental testing: Both parents are tested to confirm each carries one copy of the mutation (confirming autosomal recessive inheritance). This is called segregation analysis.
• Variant classification: The identified mutation is evaluated as pathogenic, likely pathogenic, variant of uncertain significance (VUS), likely benign, or benign using ACMG guidelines. Known PUS7 mutations from published cases are classified as pathogenic.
• Functional studies (research only): In some cases, researchers may study the effect of the mutation on PUS7 enzyme activity in cell cultures. This is not required for clinical diagnosis but helps confirm novel variants.

Citation: de Brouwer APM et al. Variants in PUS7 cause intellectual disability with speech delay, microcephaly, short stature, and aggressive behavior. Am J Hum Genet. 2018;103(6):1045–1052. PMC6288278

This landmark paper was the first to identify PUS7 as a disease gene. The study described 6 patients from 3 consanguineous families:

• Family 1 (Pakistani origin): 3 siblings, all homozygous for a frameshift mutation c.89_90del. This two-base-pair deletion disrupts the reading frame early in the gene, producing a severely truncated, non-functional protein.
• Family 2 (Syrian origin): 2 siblings, homozygous for a nonsense mutation c.1348C>T (p.Arg450*). This mutation creates a premature stop codon at position 450, truncating the protein before the TruD domain is complete.
• Family 3 (Moroccan origin): 1 patient, homozygous for a deletion of exon 15. This large deletion removes a critical portion of the gene.

Key scientific findings:

• The researchers created a Drosophila (fruit fly) model by knocking out the PUS7 homolog. The PUS7-knockout flies showed behavioral defects that were rescued by neuronal-specific PUS7 expression, providing direct proof that PUS7 enzyme activity is essential specifically in neurons.
• The study demonstrated that PUS7 deficiency abolished pseudouridylation at position 13 of cytosolic tRNAs, confirming the molecular mechanism of disease.
• All 6 patients presented with intellectual disability, speech delay, short stature, microcephaly, and behavioral challenges including aggression, establishing the core clinical phenotype.

Why this matters for families: This paper established PUS7 deficiency as a real, defined medical condition and proved that the enzyme is essential for brain function. The fly model rescue experiment is particularly important because it demonstrates that restoring PUS7 function in neurons can reverse neurological defects — a foundational finding for gene therapy.

Citation: Shaheen R et al. PUS7 mutations impair pseudouridylation in humans and cause intellectual disability and microcephaly. Hum Genet. 2019;138(3):231–239. PMC7607903

This study, published independently by the group at King Faisal Specialist Hospital in Saudi Arabia, described 3 patients from 2 additional consanguineous families:

• Family 4 (Egyptian origin): Patients homozygous for a frameshift mutation, leading to a truncated, non-functional PUS7 protein.
• Family 5 (Saudi origin): Patients homozygous for a missense mutation D503Y (p.Asp503Tyr). This mutation changes aspartate to tyrosine at position 503 within the TruD domain of the enzyme, abolishing its enzymatic activity.

Key contributions:

• Expanded the total number of known patients from 6 to 9.
• Identified new PUS7 variants including the first missense mutation in the TruD domain (D503Y), demonstrating that even single amino acid changes can completely abolish enzyme function when they affect critical residues.
• Confirmed the core clinical phenotype described by de Brouwer et al. across patients from different ethnic backgrounds, strengthening the genotype-phenotype correlation.

Why this matters for families: Independent confirmation by a second research group in different patient populations solidified PUS7 deficiency as a well-defined condition. The identification of the D503Y missense mutation in the TruD domain also showed that the specific location of a mutation within the gene matters for understanding its effect.

Citation: Darvish H et al. A novel PUS7 mutation in a family with intellectual disability. Neurol Genet. 2019;5(6):e356. DOI: 10.1212/NXG.0000000000000356

This study described 2 siblings from 1 consanguineous family of Afghani origin:

• Both siblings were homozygous for a missense mutation G128R (p.Gly128Arg), which changes glycine to arginine at position 128 in the protein.
• The patients presented with a milder phenotype compared to previously reported cases, suggesting that the G128R variant may be hypomorphic — meaning it reduces but does not completely eliminate PUS7 enzyme activity.

Key contributions:

• Expanded the total patient count from 9 to 11.
• Introduced the concept that PUS7 deficiency may exist on a severity spectrum depending on how much residual enzyme activity a particular mutation allows. Patients with some remaining enzyme function (hypomorphic variants) may have milder symptoms.
• The G128R variant is located outside the TruD domain, which may explain why it retains partial activity.

Why this matters for families: This finding is important because it suggests that not all PUS7 mutations are equal. Families whose child carries a missense mutation (especially one outside the TruD domain) may see a milder course. It also has implications for gene therapy dosing — even partial restoration of PUS7 activity could produce meaningful clinical benefit.

Citation: Han L et al. PUS7 deficiency in human patients causes profound neurodevelopmental phenotype by dysregulating protein translation. Mol Genet Metab. 2022;135(3):221–226. PMC8958514

This study described 2 siblings identified through the NIH Undiagnosed Diseases Program (UDP):

• These were the first compound heterozygous patients — meaning they inherited two different PUS7 mutations, one from each parent: a splice site mutation c.398+1G>T and a missense mutation T387M (p.Thr387Met).
• Critically, the parents were not consanguineous (not related to each other). All previously reported PUS7 families had been consanguineous. This demonstrated that PUS7 deficiency can occur in any population, not only in communities where consanguineous marriage is common.

Key molecular findings:

• Elevated MYC protein: Patient cells showed increased levels of MYC, a protein that regulates cell growth and proliferation. Overactive MYC may contribute to the developmental abnormalities seen in PUS7 deficiency.
• Decreased HPRT1 protein: Patient cells showed reduced levels of HPRT1 (hypoxanthine-guanine phosphoribosyltransferase 1), an enzyme critical for purine recycling. Complete loss of HPRT1 causes Lesch-Nyhan syndrome, which features severe self-injurious behavior. The partial decrease in HPRT1 may explain the Lesch-Nyhan-like self-injurious behavior observed in some PUS7 patients.
• Impaired tRNA-derived fragment (tRF) activity: The study showed that PUS7 deficiency disrupts the generation and function of tRNA-derived fragments, small regulatory RNA molecules that play roles in gene regulation. This revealed an additional layer of molecular disruption beyond the known tRNA modification defect.

Why this matters for families: This paper was groundbreaking for three reasons. First, it showed PUS7 deficiency is not limited to consanguineous families. Second, the MYC and HPRT1 findings provide potential biomarkers that could be used to measure disease severity and treatment response. Third, the HPRT1 connection offers a molecular explanation for self-injurious behavior, which is one of the most distressing features for families and could potentially be a target for specific therapeutic intervention.

Citation: Muda AO et al. A novel PUS7 variant in a patient with intellectual disability. Am J Med Genet A. 2023. DOI: 10.1002/ajmg.a.63212

This study described 1 male infant with a novel homozygous truncating variant c.329_332delCTGA:

• This four-base-pair deletion causes a frameshift that produces a severely truncated, non-functional PUS7 protein.
• The patient presented with the characteristic features of PUS7 deficiency including intellectual disability, speech delay, and microcephaly.

Key contributions:

• Provided the most comprehensive clinical comparison across all published PUS7 deficiency cases to date.
• Explicitly stated that as of 2023, PUS7 deficiency had been described in 15 patients with different pathogenic variants but similar clinical phenotypes, confirming the consistency of the condition across diverse mutations and ethnic backgrounds.
• Added a new truncating variant to the growing list of known PUS7 mutations.

Why this matters for families: This paper provides the most up-to-date clinical overview and confirms that despite different mutations and ethnic origins, PUS7 deficiency produces a recognizable and consistent clinical pattern. The clinical comparison table in this paper is a valuable reference for clinicians encountering PUS7 deficiency for the first time.

Citation: Naseer MI et al. A novel homozygous mutation in PUS7 gene causes intellectual disability. Saudi J Biol Sci. 2020;27(9):2297–2301.

This report described a Saudi patient with a novel homozygous frameshift variant c.606_607delGA (p.Ser282CysfsTer9):

• The two-base-pair deletion causes a frameshift at serine 282, creating a premature stop codon 9 residues downstream. The resulting protein is severely truncated and non-functional.
• The patient presented with the characteristic features of PUS7 deficiency including intellectual disability.
• This variant is not included in OMIM’s 7 selected allelic entries but further expands the mutational spectrum of PUS7 deficiency.

Why this matters for families: This report adds another confirmed pathogenic variant to the growing list, demonstrating that PUS7 mutations continue to be discovered across different populations. Every new case helps build the evidence base that will be needed for future therapeutic development.

1. Normal: PUS7 enzyme converts uridine to pseudouridine at position 13 of specific tRNAs.
2. This modification: Helps the tRNA fold into its correct three-dimensional shape.
3. Correct folding: Allows the tRNA to accurately deliver amino acids during protein synthesis at the ribosome.
4. Result: Proteins are made correctly, and cells develop and function normally.

When PUS7 is absent or non-functional:

1. Missing modification: tRNAs lack pseudouridine at position 13.
2. Impaired folding: Affected tRNAs may not function efficiently.
3. Translation errors: Protein synthesis becomes less accurate or less efficient.
4. Downstream effects: Loss of Ψ13 leads to codon-specific translational dysregulation, resulting in both elevated MYC protein (a growth and proliferation regulator) and decreased HPRT1 protein (needed for purine recycling) independently — both at the translational level, as parallel consequences of the same defect rather than one causing the other. These changes are thought to disrupt normal brain development during critical periods.

The brain is the most rapidly developing and metabolically demanding organ during fetal life and early childhood. Brain cells (neurons) require massive amounts of protein synthesis to form connections (synapses), migrate to their correct positions, and build myelin insulation. Even small disruptions to translation accuracy can have outsized effects on brain development compared to other organs. This is why PUS7 deficiency — and many other tRNA modification disorders — primarily manifests as intellectual disability and neurological symptoms.

It is fair to ask: if there is no medicine that fixes PUS7 deficiency, why does having the exact genetic diagnosis matter? The answer is that a precise diagnosis does a great deal of good even when it does not change a single medication. It ends the uncertainty and the testing. No more wondering, no more rounds of inconclusive investigations chasing other possibilities — you have a name and an explanation, and that alone brings many families a measure of peace and the ability to plan. It guides what to watch for. Knowing the diagnosis tells your team which complications are part of this condition — hearing, seizures, feeding, growth, behavior — so they can monitor for and treat them early, which is exactly where good care makes its difference. It unlocks services. A confirmed genetic diagnosis often strengthens eligibility for therapies, school supports, disability benefits, and respite programs. It makes family planning possible. Because the condition is inherited, knowing the exact gene change lets your family understand the chance of recurrence and access prenatal or pre-pregnancy testing if you wish — and lets relatives learn their carrier status. And it opens the door to research. Identified patients can join natural-history studies and registries that, over years, are what make future treatments possible at all. A diagnosis is not a cure, but it is the key that unlocks the right care, the right support, and the right connections — which is why pursuing it was worthwhile.

• What specific PUS7 mutation does my child have, and is it one that has been described before?
• Can you explain the difference between a pathogenic variant and a variant of uncertain significance?
• Should my other children or family members be tested for carrier status?
• If we plan to have more children, what are our options for genetic counseling and prenatal testing?
• Are there any research studies or patient registries we should enroll in?
• Should we send our child’s genetic data to any other laboratories for additional analysis?
• Is there a geneticist at an academic center who specializes in RNA modification disorders?

Speech therapy is one of the most important interventions and should begin as early as possible. A speech-language pathologist (SLP) can help with:

• Augmentative and alternative communication (AAC): For children who are non-verbal or have very limited speech, AAC devices (tablet-based apps, picture exchange systems, sign language) can provide a way to communicate. AAC does not prevent speech development — research consistently shows it supports it.
• Oral motor exercises: Strengthening the muscles used for speech and feeding.
• Receptive language building: Even when expressive language is limited, children can often understand much more than they can say. Building receptive language improves quality of life and reduces behavioral frustration.
• Feeding therapy: SLPs with feeding specialization can address oral aversion, texture sensitivities, and swallowing difficulties.

Frequency: Most children benefit from 2–5 sessions per week during early childhood. Frequency can be adjusted as the child grows.

• Fine motor skills: Grasping, self-feeding, dressing, handwriting (or alternatives)
• Sensory integration: Many children with PUS7 deficiency have sensory processing differences. OT can help with sensory diets, desensitization programs, and environmental modifications.
• Self-care skills: Toileting, hygiene, eating independently — building as much independence as possible
• Adaptive equipment: Specialized utensils, seating, dressing aids

• Hypotonia management: Exercises to build core strength, improve posture, and support gross motor development
• Gross motor milestones: Rolling, sitting, crawling, walking — each child’s timeline will be individual
• Balance and coordination: Activities to improve stability and reduce fall risk
• Orthotic evaluation: Some children may benefit from ankle-foot orthoses (AFOs) for gait support

Aggression, self-injurious behavior, and other behavioral challenges are among the most difficult aspects of PUS7 deficiency for families. A multi-pronged approach is most effective:

• Applied Behavior Analysis (ABA): Evidence-based behavioral therapy that uses reinforcement strategies to increase helpful behaviors and decrease harmful ones. ABA should be provided by a Board Certified Behavior Analyst (BCBA). Some families find ABA very helpful; others prefer less structured approaches. Work with your team to find what fits your child.
• Positive Behavioral Support (PBS): Focuses on understanding why a behavior occurs (its function) and modifying the environment or teaching replacement behaviors.
• Environmental modifications: Reducing sensory overload, creating predictable routines, providing safe spaces for de-escalation.
• Medication (if needed): For severe aggression or self-injury that does not respond to behavioral approaches, a behavioral pediatrician or child psychiatrist may consider medications. Options should be discussed carefully with your medical team, as children with intellectual disability may respond differently to medications and are more susceptible to side effects.

• Regular audiological assessment: Hearing should be tested at diagnosis and at least annually thereafter. Hearing loss may be progressive in some patients.
• Hearing aids: For children with sensorineural hearing loss, appropriately fitted hearing aids can significantly improve communication and development.
• Cochlear implant evaluation: For children with severe to profound hearing loss who do not benefit from hearing aids, cochlear implant evaluation should be discussed with an otolaryngologist experienced in pediatric implantation.
• FM systems for school: Personal FM systems amplify the teacher’s voice directly to the child’s hearing aids, reducing background noise.

• EEG monitoring: If seizures are suspected, an electroencephalogram (EEG) can identify seizure activity. Prolonged or overnight EEG may be needed to capture intermittent events.
• Anti-seizure medications: Standard anti-epileptic drugs (AEDs) are used. The choice of medication depends on seizure type, age, and other medications. There is no PUS7-specific seizure medication; treatment follows standard epilepsy guidelines.
• Seizure action plan: Every child with seizures should have a written seizure action plan shared with school, daycare, and all caregivers. This includes when to administer rescue medication and when to call 911.
• Rescue medication: Diazepam rectal gel (Diastat) or midazolam nasal spray (Nayzilam) should be prescribed for children with seizures, with training provided to all caregivers.

• Caloric supplementation: Children with oral aversion and poor weight gain may need calorie-dense formulas or supplements.
• Texture progression: Work with an SLP or OT trained in feeding therapy to gradually introduce textures. Never force feeding — this worsens oral aversion.
• Gastrostomy tube (G-tube): If oral feeding is insufficient to maintain growth, a G-tube may be recommended. This is not a failure — it ensures adequate nutrition while oral feeding therapy continues. Many children eventually transition to full oral feeding.
• Growth monitoring: Regular weight, height, and head circumference measurements, plotted on growth charts. Because PUS7 patients are typically small, use the child’s own growth trajectory, not just standard percentiles.
• Nutritionist/dietitian: A pediatric nutritionist can help optimize caloric intake and ensure micronutrient adequacy.

• Sleep hygiene: Consistent bedtime routine, dark and quiet room, no screens before bed, regular wake time.
• Melatonin: Low-dose melatonin (0.5–3 mg) is commonly used and generally well-tolerated in children with neurodevelopmental disorders. Start with the lowest dose. Discuss with your pediatrician.
• Sleep study: If sleep apnea is suspected (loud snoring, pauses in breathing), a polysomnography study should be performed.
• Weighted blankets and sensory strategies: Some children sleep better with deep-pressure sensory input. Ensure safe use per age guidelines.

Some of the most effective support happens not in a clinic but in the texture of everyday life at home, and small adjustments add up. Predictable routines are powerful: many children with PUS7 deficiency are calmer and more able when the day has a familiar shape, and when changes are signaled in advance rather than sprung — a visual schedule (pictures of the day's activities) turns the uncertain into something a child can anticipate, and a warning before transitions ("two more minutes, then we'll clean up") prevents many meltdowns. Sensory needs are common and individual: some children are overwhelmed by noise, bright light, crowds, or certain textures, while others seek movement and deep pressure. Learning your child's particular sensitivities — with help from an occupational therapist — lets you shape the environment to fit them: a calmer, less cluttered space; noise-reducing headphones for loud places; comfortable clothing; and a designated quiet "calm-down" spot your child can retreat to when overwhelmed. Keeping favorite comfort items, AAC tools, and a few familiar activities within reach supports regulation through the day. The goal is not a rigid or clinical home but a predictable, sensory-friendly one that works with your child's nervous system rather than against it — which makes daily life smoother for everyone and frees energy for play, connection, and the ordinary joys of childhood.

If there is one area where effort pays off more than almost any other, it is communication. Speech and language difficulty is the most universal feature of PUS7 deficiency, and many children are non-verbal or minimally verbal — but not speaking is not the same as having nothing to say, and not communicating in the usual way is not the same as not understanding. The goal is to give your child a reliable way to express themselves, in whatever form works for them. This is where augmentative and alternative communication (AAC) comes in: picture-exchange systems, communication boards, sign language, and speech-generating devices or tablet apps that "speak" when your child selects pictures or words. An important and reassuring fact for worried parents: AAC does not hold back speech — research shows it often supports spoken-language development, and it never forecloses it. A speech-language pathologist experienced in AAC should be involved early, ideally evaluating your child well before the preschool years, and the whole family and school should learn to use whatever system is chosen so your child has consistent access to it everywhere. The payoff is large and goes beyond words: when a child can finally make a need, a refusal, or a discomfort understood, frustration drops and so, often, do the difficult behaviors that grew out of not being understood. Presume your child has things to tell you, and invest in giving them the means.

Sleep problems are common in PUS7 deficiency and they ripple through everything — a poorly slept child is more irritable, has more difficult behavior and seizures, and learns less, while exhausted parents have less in the tank for everything else — so improving sleep is one of the highest-value things a family can work on. Start with the foundations, which genuinely help even when they feel basic. A consistent routine — the same calming sequence of activities at the same time each night, often supported by a visual bedtime schedule — signals the body that sleep is coming. The sleep environment matters: dark, cool, and quiet, with screens off well before bed, since screen light delays sleep. Daytime habits feed nighttime sleep — regular wake times, activity and natural light during the day, and care with late naps. If good routines are not enough, melatonin is commonly used and generally well tolerated in children with neurodevelopmental conditions to help with falling asleep (and extended-release forms can help with staying asleep) — discuss dose and timing with your doctor rather than starting on your own. Finally, if your child snores, gasps, or seems to stop breathing in sleep, ask about a sleep study to check for sleep apnea, which is treatable and an important cause of disrupted sleep. Small, consistent changes often add up to meaningful improvement, with benefits for the whole family.

Aggression, self-injury, and meltdowns are among the hardest parts of daily life for many families, and the single most useful idea is this: in a child who cannot easily talk, behavior is communication. A behavior that looks like "acting out" is very often your child telling you something they have no other way to say — that they are in pain, frightened, overwhelmed, or unable to make a need understood. This reframe changes what you do. When behavior worsens, the first question is not "how do I stop this?" but "what is my child trying to tell me?" The most common hidden causes are physical and easily missed in a child who cannot point to what hurts: dental pain, constipation, ear infections, reflux, or a change in hearing — all worth checking before assuming the behavior is "just the condition." Other frequent triggers are sensory overload (noise, lights, crowds), hunger or tiredness, and the frustration of not being understood. Two things help most over time: a reliable way to communicate — a picture system, device, or signs (AAC) — which directly reduces the frustration behind much aggression, and predictable routines with warnings before transitions. Medication has a place for severe, dangerous behavior that does not respond to these steps, but it works best alongside communication and comfort, never instead of looking for the message underneath. Keeping a simple log of what happened right before and after difficult episodes often reveals the pattern.

Beyond the headline issues, some ordinary health matters carry extra weight for a child who cannot easily tell you when something hurts, and staying ahead of them prevents a lot of trouble. Dental care deserves special mention because tooth pain is common, easily missed in a non-verbal child, and a frequent hidden cause of worsening behavior — so establish care with a dentist experienced in special needs early, keep to regular cleanings (some children need sedation for thorough exams or treatment), and consider dental pain whenever behavior changes for no obvious reason. Constipation is similarly common and similarly able to drive discomfort and behavior; watch for it and treat it proactively with fluids, fiber, and your doctor's recommended measures. Illnesses can hit harder and present atypically — a child may show an infection through irritability or off behavior rather than complaint — so trust changes from baseline, and have a low threshold to check for ear infections, urinary infections, and the like. Keep vaccinations up to date (there is no reason to skip them, and infections are riskier in medically complex children), and ask your team about flu and other seasonal protection. Finally, keep a simple, current health summary — diagnosis, medications, allergies, baseline behaviors, how your child communicates pain — that you can hand to any new clinician or emergency department, since the people most likely to treat your child in a crisis are the least likely to know them. A little proactive, ordinary health maintenance prevents many of the escalations that otherwise land families in the emergency room.

• What therapies should we start right now, and how many hours per week?
• Should my child have a formal hearing evaluation, and how often should it be repeated?
• Does my child need an EEG to check for seizure activity?
• Is my child’s growth adequate, or should we consider nutritional supplementation?
• What behavioral strategies work best for children with intellectual disability and aggression?
• Should we get an AAC evaluation for communication?
• Is there a sleep specialist we should see?
• How do we coordinate care among all the specialists?

MOST FEASIBLE Adeno-associated virus serotype 9 (AAV9) gene replacement therapy is the most scientifically feasible approach for PUS7 deficiency. Here is why:

• AAV9 crosses the blood-brain barrier: When delivered intravenously, AAV9 can reach brain cells (neurons and glial cells). This is critical because PUS7 deficiency primarily affects the brain. This is the same vector used in Zolgensma (onasemnogene abeparvovec), the approved gene therapy for spinal muscular atrophy (SMA).
• PUS7 fits in the AAV payload: AAV vectors can carry approximately 4.7 kilobases (kb) of DNA. The PUS7 coding sequence is well within this limit, so the entire gene plus regulatory elements can be packaged in a single AAV particle.
• Loss-of-function mechanism: PUS7 deficiency is caused by loss of enzyme function (not gain of toxic function). This means adding a working copy should be sufficient — you do not need to remove or silence the mutant gene, which simplifies the therapy enormously.
• Proven precedent: Zolgensma demonstrates that AAV9-based gene therapy can treat a neurodevelopmental condition when administered in infancy. Multiple other AAV gene therapies for rare diseases are in clinical trials or approved (Luxturna for inherited blindness, Hemgenix for hemophilia B).

What would PUS7 gene therapy look like? Based on existing AAV9 therapies:

• A single intravenous infusion, likely in infancy or early childhood for maximum benefit
• Hospitalization for a few days for monitoring
• Immunosuppression (steroids) to prevent immune reactions against the vector
• Monitoring of liver function (AAV vectors are processed by the liver)
• Potential for lasting effect, as neurons are long-lived cells

Families often ask about CRISPR gene editing, especially after the approval of Casgevy (exagamglogene autotemcel) for sickle cell disease. It is important to understand why this specific approach does not apply to PUS7 deficiency:

• Wrong tissue: Casgevy works by editing blood stem cells that are removed from the body, edited in a laboratory, and transplanted back. PUS7 deficiency affects the brain, and brain cells cannot be removed, edited, and returned.
• Wrong strategy: Casgevy does not fix the sickle cell mutation. Instead, it reactivates fetal hemoglobin (a separate gene) to compensate. There is no equivalent compensatory mechanism for PUS7.
• Delivery challenge: CRISPR components cannot easily cross the blood-brain barrier to reach neurons in sufficient numbers.

This does not mean gene editing will never be useful for PUS7 — just that the Casgevy model does not apply directly.

Why AAV gene replacement is preferred over CRISPR for PUS7: Beyond the Casgevy-specific issues above, CRISPR gene editing in general faces several challenges for PUS7 deficiency. The Cas9 protein used in CRISPR is very large (~4.2 kb for SpCas9 alone), leaving almost no room for additional cargo in an AAV vector. Delivering CRISPR components to enough brain cells is far more difficult than delivering a small replacement gene. Because PUS7 deficiency is a loss-of-function disorder, simply adding a working copy of the gene is sufficient — there is no need to correct or remove the broken copy, which greatly simplifies AAV gene replacement compared to CRISPR editing. For these reasons, AAV9-based gene addition remains the most practical near-term strategy.

THEORETICAL Base editing is a newer, more precise form of gene editing that can change a single DNA letter without cutting the DNA double strand. For PUS7 patients with specific missense mutations (like G128R or D503Y), base editing could theoretically correct the exact mutation and restore a normal PUS7 protein.

Advantages: Fixes the actual mutation rather than adding a second gene copy. More precise than traditional CRISPR. Less risk of unwanted DNA changes.

Barriers: Delivery to the brain remains challenging. Base editors are large molecules that are difficult to package in AAV vectors. Technology is advancing rapidly but is not yet ready for clinical application in brain disorders. Would need to be tailored to each specific mutation.

THEORETICAL mRNA therapy would deliver synthetic PUS7 messenger RNA (similar to COVID-19 mRNA vaccines) to cells, providing temporary instructions to make the PUS7 enzyme. This approach would require repeated administration (unlike a one-time gene therapy) because mRNA degrades within days. Delivery to the brain is the major obstacle. Intrathecal (spinal) delivery of mRNA to the central nervous system is being explored for other conditions. This approach is in very early research stages for any brain disorder.

For some missense mutations where the PUS7 protein is made but folds incorrectly, pharmacological chaperone molecules could theoretically stabilize the misfolded protein and restore partial activity. This approach has shown promise in other enzyme deficiency disorders (e.g., migalastat for Fabry disease). No chaperone molecules have been identified or tested for PUS7, but the concept is worth monitoring as more is learned about PUS7 protein structure.

For PUS7 patients with splice-site mutations, antisense oligonucleotides (ASOs) could theoretically redirect splicing to produce functional mRNA. This approach is used in nusinersen (Spinraza) for SMA. ASOs can be delivered to the central nervous system via intrathecal injection. This would need to be custom-designed for each splice mutation.

• Has anyone submitted PUS7 to the BGTC for consideration?
• Is there a PUS7 knockout mouse model being developed or already available?
• Are there any active research grants studying PUS7 enzyme function?
• How can our family contribute tissue samples, medical records, or developmental data for research?
• Is anyone developing gene therapy for related epitranscriptomic disorders that could inform PUS7 therapy?
• What is the estimated cost of the preclinical work needed, and are there grants available?

• Life expectancy: PUS7 deficiency is not expected to be life-limiting based on current data. No deaths have been reported among known patients. The condition primarily affects neurodevelopment, not vital organ function.
• Intellectual level often stabilizes: While intellectual disability is present from early life, cognitive abilities typically plateau rather than decline. Children continue to learn and develop new skills, albeit at a slower pace than peers.
• Microcephaly: Head circumference may continue to fall behind age norms during the first years of life as the brain grows more slowly. This does not necessarily mean ongoing brain deterioration — it reflects the initial developmental difference.
• Seizures: When seizures occur, they can often be managed with standard anti-epileptic medications. Seizure risk and type may change over time — monitoring is important throughout life.
• Hearing: Hearing loss, when present, may be stable or progressive. Lifelong audiological monitoring is recommended.

• Only ~15 patients are known. All currently identified patients are still young (children or young adults). We do not yet have data on PUS7 deficiency in middle age or later life.
• Long-term health complications: Whether PUS7 deficiency causes additional health issues beyond the known features (for example, bone health, endocrine function, cardiac issues) is not yet established.
• Individual variation: With so few patients, we cannot reliably predict the range of outcomes. Some patients have relatively milder presentations while others are more severely affected. We do not yet understand what drives this variation.
• Response to therapy: It is not known how much improvement is possible with intensive early intervention, because most known patients were diagnosed after the earliest therapeutic windows.

One of the quieter challenges of raising a child with significant developmental differences is the constant, often unconscious comparison — to typically developing children, to milestone charts, to what you once imagined. A gentler and more accurate way to measure your child's life is against their own path. Children with PUS7 deficiency do continue to learn and grow; the trajectory is one of steady, individual progress rather than loss, and development tends to unfold on its own timeline rather than the standard one. Progress may look different than the textbook — a first reliable way to say "more" with a picture or device, learning to tolerate a new food or a haircut, a stretch of better sleep, a new sign, more settled behavior, a moment of clear connection — and these are real, hard-won achievements worth celebrating fully, not consolation prizes. Many parents find it helps to keep a simple record of the small steps, both because progress is easy to forget in the daily grind and because seeing the accumulation over months and years is genuinely encouraging. It also helps to define success in terms of quality of life and participation — comfort, joy, connection, inclusion, and the chance to do the things your child enjoys — rather than only in terms of developmental milestones. Your child's worth was never measured by a chart, and meeting them where they are, while supporting each next step, is both kinder and closer to the truth of how they grow.

Feeding and Nutrition

• Many infants with PUS7 deficiency have oral aversion and feeding difficulties. Work with an SLP who specializes in pediatric feeding.
• Texture progression should be gradual and child-led. Never force foods — this worsens aversion.
• If weight gain is inadequate despite feeding therapy, discuss caloric supplementation or G-tube placement with your pediatrician and gastroenterologist. A G-tube is a tool, not a defeat.

Early Intervention (Birth to 3)

• In the United States, the Individuals with Disabilities Education Act (IDEA) Part C provides free early intervention services for children birth to 3 with developmental delays. Contact your state’s early intervention program immediately after diagnosis.
• Services typically include: speech therapy, occupational therapy, physical therapy, developmental specialist visits, and family training — all provided in the home.
• The earlier services begin, the better the outcomes. Do not wait for a genetic diagnosis to start early intervention — developmental delay alone qualifies your child.

Communication

• Introduce augmentative and alternative communication (AAC) early. Options include: picture exchange communication system (PECS), sign language (Baby Sign or ASL), and AAC apps on tablets (Proloquo2Go, TouchChat, LAMP Words for Life).
• AAC does not prevent speech development. Research consistently shows that AAC supports and accelerates language acquisition, even in children who eventually develop verbal speech.
• Total communication approach: use speech, sign, pictures, and gestures simultaneously to maximize understanding.

Hearing

• Hearing screening at birth (newborn hearing screen) and at diagnosis. If hearing loss is identified, audiological follow-up every 3–6 months in early childhood.
• Early hearing aid fitting is critical — even mild hearing loss can compound speech and language delays.
• Discuss cochlear implant candidacy if hearing loss is severe to profound.

Hypotonia and Motor Development

• Physical therapy 2–3 times per week to build core strength and support gross motor milestones.
• Positioning aids (supportive seating, tummy time supports) to promote development.
• Milestones will be delayed but many children do learn to sit, stand, and walk. Celebrate every achievement.

Sensory Integration

• OT with sensory integration training can help children who are over- or under-responsive to sensory input (light, sound, touch, movement).
• Sensory diets (planned sensory activities throughout the day) can reduce behavioral meltdowns and improve attention.

Education Rights and IEP

• In the United States, IDEA Part B guarantees a free appropriate public education (FAPE) for all children with disabilities from age 3 to 21.
• Your child is entitled to an Individualized Education Program (IEP) that specifies: educational goals, specialized instruction, related services (speech, OT, PT), accommodations, and placement.
• You are an equal member of the IEP team. Bring documentation from all providers. You have the right to request evaluations, dispute decisions, and request independent educational evaluations (IEEs) at district expense.
• Placement options range from full inclusion with support, to self-contained special education classrooms, to specialized schools. The right placement depends on your child’s needs.

Behavioral Management

• Aggression and self-injurious behavior may increase during school years due to communication frustration, sensory overload, or difficulty with transitions.
• Functional Behavior Assessment (FBA) should be conducted to understand the triggers and functions of challenging behaviors.
• A Behavior Intervention Plan (BIP) in the IEP provides strategies for school staff.
• Consistency between home and school approaches is critical. Regular communication between the behavioral team and school staff.
• Physical restraint and seclusion should be absolute last resorts. Know your state’s laws on these practices in schools.

Social Development

• Structured social skills groups (often led by SLPs or social workers) can teach turn-taking, greeting, personal space, and emotion recognition.
• Best Buddies and similar programs pair children with and without disabilities for friendship.
• Inclusive extracurricular activities: adaptive sports, therapeutic horseback riding (hippotherapy), adaptive swim programs, art therapy, music therapy.

Managing Seizures in School

• A written seizure action plan must be in the student’s health file. All staff who interact with the child should be trained.
• Rescue medication (diazepam or midazolam) must be available at school with trained personnel to administer it.
• School nurse involvement is essential. If your school does not have a full-time nurse, advocate for trained seizure response personnel.

Recreation and Physical Activity

• Special Olympics provides sports training and competition for individuals with intellectual disabilities starting at age 8. Programs are available in all 50 US states and many countries worldwide.
• Adaptive swimming, martial arts, and dance can build strength, coordination, and self-confidence.
• Summer camps for children with special needs provide structured recreation and respite for families.

Puberty and Body Changes

• Puberty typically occurs at the normal age in children with PUS7 deficiency (though this is not definitively established due to the small number of known patients).
• Prepare your child for bodily changes using visual social stories and concrete, simple language appropriate to their understanding.
• Menstrual management for girls: discuss options with your pediatrician or gynecologist, including menstrual hygiene training, hormonal management if needed, and adaptive products.

Behavioral Changes

• Hormonal changes during puberty may increase behavioral challenges, including aggression, mood swings, and sexual behaviors.
• Re-evaluate behavioral plans and consider whether medication adjustments are needed.
• Adapted sexuality education is important: body autonomy, appropriate vs. inappropriate touch, private vs. public behaviors. Resources exist specifically for individuals with intellectual disabilities.

Guardianship Planning (Begin at 17)

• In most US states, parental authority over medical and financial decisions ends at age 18. If your child cannot make independent decisions, you will need legal guardianship or conservatorship.
• Start the process at age 17 because court proceedings take time. Consult a special needs attorney.
• Options range from full guardianship to limited guardianship to supported decision-making agreements, depending on your child’s capacity. Use the least restrictive option that keeps your child safe.

Transition Planning (School to Adult Services)

• IDEA requires transition planning to begin no later than the IEP in effect when the student turns 16 (some states start at 14).
• The transition plan should address: post-secondary education or training, employment or day program, community living, recreation, and adult services.
• Apply for Supplemental Security Income (SSI) at age 18 — the child’s income (not parents’) is evaluated at that point.
• Connect with your state’s Division of Services for People with Disabilities (DSPD) or equivalent agency before age 18. Waiting lists for services can be years long.

Building Independence

• Focus on functional life skills: money concepts (even if simplified), crossing streets safely, using public transportation (if appropriate), personal hygiene routines, cooking simple foods.
• Every skill that builds independence improves quality of life, even if full independence is not achievable.

Day Programs and Supported Employment

• Day programs provide structured activities, social interaction, skill building, and community participation for adults with intellectual disabilities.
• Supported employment programs provide job coaching, workplace accommodations, and ongoing support for adults who can work in competitive or customized positions.
• Vocational rehabilitation services (state-run) can help identify appropriate work or program options.

Residential Options

• Family home: Many adults with intellectual disabilities live with family, especially when community-based services are limited.
• Group homes: Staffed residential settings with 3–8 residents, providing 24-hour support while promoting community integration.
• Supported living: An apartment or house with staff support for some hours of the day, for individuals with greater independence.
• Host home / shared living: A caregiver shares their home with an adult with disabilities, providing a family-like setting.
• Waiting lists: In many states, waiting lists for residential services are years or even decades long. Apply early. Get on every list you might need.

Government Benefits

• Supplemental Security Income (SSI): Monthly cash benefit for individuals with disabilities who have limited income and resources. Apply at age 18 through Social Security.
• Medicaid: SSI recipients automatically qualify for Medicaid in most states, which covers medical care, therapies, and waiver services.
• Medicaid Waivers (HCBS): Home and Community Based Services waivers fund services like personal care, day programs, supported employment, respite, and residential support. Each state has different waivers with different services and waiting lists.
• ABLE Accounts: Tax-advantaged savings accounts for individuals with disabilities (onset before age 26). Funds can be used for disability-related expenses without affecting SSI or Medicaid eligibility (up to $100,000).

Long-Term Health Monitoring

• Hearing: Annual audiological assessment throughout life.
• Seizures: If seizures are present, ongoing neurological follow-up and medication management.
• Bone health: Individuals with limited mobility and small stature may be at risk for osteoporosis. Discuss bone density screening with the primary care physician.
• Dental: Regular dental care, which may require sedation or general anesthesia for individuals who cannot cooperate with dental procedures. Find a dentist experienced with special needs patients.
• Mental health: Depression and anxiety can be difficult to recognize in individuals with intellectual disability. Changes in behavior, appetite, or sleep may be indicators.

Planning for When Parents Can No Longer Provide Care

• Special Needs Trust: A trust that holds assets for your child’s benefit without disqualifying them from SSI or Medicaid. Consult a special needs attorney to set this up.
• Letter of Intent: A non-legal document that describes your child’s daily routine, preferences, medical needs, and your wishes for their care. Update it regularly and share with the successor guardian.
• Successor guardian: Identify and have a conversation with the person(s) who will assume guardianship if you become unable to serve. This might be a sibling, other family member, or professional guardian.
• Residential placement timeline: Some families choose to transition to residential living while they are still able to oversee the adjustment, rather than waiting for a crisis.

• Burnout is real and it is not your fault. The chronic demands of caregiving — disrupted sleep, behavioral crises, constant appointments, advocacy battles, financial stress — can lead to caregiver burnout, depression, and anxiety. These are medical conditions that deserve treatment, not evidence of weakness.
• Respite care is essential, not optional. Respite care provides temporary breaks for caregivers. It may be provided by: trained respite workers (through Medicaid waivers), family members, church or community groups, or specialized respite facilities. Apply for respite hours through your state’s disability services. Use them without guilt.
• Therapy for caregivers: Individual therapy or counseling for parents is not a luxury. Find a therapist who understands disability parenting. Your emotional health directly affects your ability to care for your child.
• Support groups: While there is no PUS7-specific support group (the community is too small), broader groups for parents of children with intellectual disabilities, rare diseases, or undiagnosed conditions can provide community and understanding. Organizations include: NORD (National Organization for Rare Disorders), Global Genes, and local parent support groups through The Arc.

• Typically-developing siblings of children with disabilities experience a unique set of challenges: reduced parental attention, embarrassment in social situations, premature maturity, and sometimes caregiving responsibilities.
• They also develop remarkable strengths: empathy, patience, advocacy skills, and resilience.
• The Sibling Support Project (siblingsupport.org) offers Sibshops — facilitated workshops for school-age siblings of children with special needs. Available in many communities.
• Give each sibling one-on-one time regularly. It does not have to be elaborate — 30 minutes of undivided attention matters enormously.
• Be honest with siblings about the diagnosis in age-appropriate language. Children handle truth better than uncertainty.
• Watch for signs of emotional distress in siblings and offer professional support if needed.

• Genetic counseling is strongly recommended for any family with a PUS7-affected child who is considering future pregnancies.
• Each pregnancy has a 25% chance of producing a child with PUS7 deficiency (because both parents are carriers).
• Prenatal testing options: Chorionic villus sampling (CVS) at 10–13 weeks or amniocentesis at 15–20 weeks can test the fetus for the known family mutations. Preimplantation genetic testing (PGT) with in vitro fertilization (IVF) can test embryos before pregnancy.
• Carrier testing for siblings: As siblings reach reproductive age, they can be tested for carrier status. If a sibling is a carrier and their partner is also a carrier (rare for PUS7 given its extreme rarity), their children would be at risk.
• Consanguinity counseling: Several known PUS7 families are from consanguineous (related parent) backgrounds. If this applies to your family, genetic counseling can discuss the implications for extended family members.

• Special Needs Trust (SNT): A trust designed to hold assets for a person with disabilities without affecting their eligibility for government benefits (SSI, Medicaid). There are first-party and third-party trusts with different rules. Consult a special needs attorney.
• ABLE Account: Achieving a Better Life Experience (ABLE) accounts are tax-advantaged savings accounts for individuals whose disability onset occurred before age 26. Contributions up to $18,000/year (2026). First $100,000 in an ABLE account is excluded from SSI resource limits.
• Government benefits navigation: The system is complex. Consider hiring a benefits planner (your state’s Work Incentive Planning and Assistance program offers free help) to maximize benefits without accidentally disqualifying your child.
• Life insurance: Consider a life insurance policy on yourself (the caregiver) that names the special needs trust as beneficiary. This ensures funds are available for your child’s care after you are gone, without affecting their benefits.

• Medical ID: Your child should wear a medical identification bracelet or necklace listing: PUS7 deficiency, seizure disorder (if applicable), non-verbal status (if applicable), emergency contacts, and any allergies or medications.
• Communication passport: A one-page document describing how your child communicates, what their behaviors mean, what calms them, what upsets them, dietary needs, and medical information. Keep copies in the school bag, car, and with all caregivers. Share with emergency responders.
• Seizure action plan: If your child has seizures, ensure all caregivers, school staff, and family members have a copy and are trained in seizure first aid and rescue medication administration.
• Hospital bag: Keep a bag packed with comfort items, AAC device and charger, communication passport, medication list, insurance cards, and seizure action plan for emergency room visits.
• First responder awareness: Consider contacting your local police and fire departments to register your child as a vulnerable person so first responders know there is a non-verbal child with special needs at your address.

The demands of raising a child with complex needs fall heavily on a couple and a family, and tending to those relationships is not a distraction from caregiving but part of what makes long-term caregiving sustainable. Partners often cope and grieve differently and on different timelines, carry uneven shares of the practical load, and can drift apart simply from never having time together — all common, and none a sign of failing. A few things help: protecting even small amounts of regular time together that is not about appointments or logistics; sharing the load and the mental work of coordination as deliberately as you can; communicating openly about how each of you is doing rather than assuming; and seeking couples counseling early, before strain becomes crisis, ideally with someone who understands disability parenting. The same care extends to the wider family. Siblings need one-on-one attention and honest, age-appropriate explanation; grandparents and extended family can be a profound support if you let them in and tell them specifically how to help. And the family as a whole benefits from still being a family that has fun — from outings, traditions, and ordinary joys adapted as needed, rather than a household organized entirely around one child's diagnosis. You cannot pour from an empty cup, and a family that protects its relationships and its capacity for joy is, in the end, better able to give your child the steady, loving care they need across many years.

With an ultra-rare condition, you will often know more about your child — and sometimes about the diagnosis itself — than the professionals you meet, and stepping into the role of expert and advocate is one of the most valuable things you can do. This is not about becoming a doctor; it is about becoming the keeper of your child's story and the coordinator of their care. A few habits make it manageable. Keep a single organized record — a binder or a folder on your phone — with the genetic report, key test results, medication list, each specialist's contact, and notes from important appointments; you will be asked for this information again and again, and having it ready saves enormous time and prevents errors. Prepare for appointments by writing down your top two or three concerns and questions in advance, and bring someone with you when you can. Ask for things in writing (referrals, plans, school documents) so there is a record. Trust your observations: you see your child across every setting and you noticed the differences that led to the diagnosis — that expertise is real, and a good clinician will welcome it. And give yourself permission to ask for a second opinion or a referral to a specialized center without worrying about offending anyone. Being organized and assertive is not being difficult; for a child with a condition few clinicians know, it is essential, and the professionals who serve you best will respect it.

You will inevitably meet doctors, nurses, therapists, and emergency staff who have never encountered PUS7 deficiency — most never will — and knowing how to handle these encounters reduces a lot of friction. The reassuring truth is that they do not need to be experts in PUS7 to help your child well, because almost everything that needs managing — seizures, behavior, hearing, feeding, development, an acute illness — is managed the same way it would be in any child with those issues. Your job is to bridge the knowledge gap efficiently. Lead with a one-line summary you can deliver from memory: for example, "My child has PUS7 deficiency, an ultra-rare genetic condition causing intellectual disability and developmental delay; today we're here about [the specific problem]." Carry a brief written summary or "communication passport" describing the diagnosis in plain terms, how your child communicates, what their behaviors mean, and key medical information — and hand it over rather than expecting busy staff to look anything up. Frame the visit around the concrete issue at hand, not the rare label. It is also completely appropriate to point clinicians to your child's geneticist or a written care plan for the genetic specifics. Most professionals respond well when you make it easy for them; you are not asking them to know everything, only to apply what they already know to your child, with your help filling in the rest.

One of the loneliest parts of an ultra-rare diagnosis is that you may never meet another family whose child has the exact same condition — there are simply too few. But connection and community are still available, and they matter enormously for both information and emotional survival. Look outward in widening circles. Rare-disease umbrella organizations — such as NORD (National Organization for Rare Disorders) and Global Genes — exist precisely for families like yours, offering resources, navigation help, and a community of people who, whatever their specific diagnosis, understand the rare-disease experience intimately. Intellectual-disability and developmental-disability communities (for example through The Arc, and condition-general parent groups) share a great deal of practical wisdom about therapies, school, behavior, and services that applies regardless of the underlying gene. Undiagnosed and ultra-rare research programs, like the NIH Undiagnosed Diseases Program and the laboratories that discovered PUS7 deficiency, can sometimes connect families studying the same condition and are how a scattered handful of patients gradually becomes a findable group. And online communities for rare disease and for the specific challenges you face (non-verbal communication, AAC, behavior, seizures) put practical experience and solidarity within reach from home. You may be the only PUS7 family in your city, but you are not alone in the broader sense — and reaching into these communities both supports you now and helps build the connections from which, over time, research and a dedicated community can grow.

Your child’s ideal care team includes:

• Clinical geneticist: Coordinates genetic diagnosis, monitors for new research, connects with research programs
• Developmental pediatrician or neurologist: Manages seizures, developmental assessment, medication oversight
• Audiologist: Hearing assessment and management
• Speech-language pathologist (SLP): Communication, feeding therapy, AAC evaluation
• Occupational therapist (OT): Fine motor, sensory integration, self-care skills
• Physical therapist (PT): Gross motor, strength, mobility
• Behavioral psychologist or BCBA: Behavioral assessment and intervention plans
• Social worker: Benefits navigation, family support, service coordination
• Primary care pediatrician: General health, immunizations, growth monitoring, care coordination

Navigating with an ultra-rare diagnosis: Most of your doctors will never have heard of PUS7 deficiency. This is normal. Bring this guide and the relevant OMIM entry (#618342) to appointments. The best doctors will be willing to learn alongside you. If a provider dismisses the condition or refuses to look at the evidence, find a different provider.

Currently, there is no formal PUS7 patient registry or family support group. With only ~15 known patients worldwide, the community is extremely small. However, connecting even a few families can be transformative:

• Ask your geneticist if they can connect you (with appropriate consent) with other PUS7 families they know of.
• Contact the research groups (Radboud University, King Faisal) and ask if they can facilitate family connections.
• NORD and Global Genes can help families of ultra-rare conditions connect and potentially establish a patient organization.
• Facebook and social media: Consider creating or joining a PUS7 family group. Some ultra-rare disease communities have formed entirely through social media.
• This guide can help: Share this guide with your medical team and any other families you connect with. Creating a shared resource is one step toward building a community.

There is no right way to feel after receiving a diagnosis of PUS7 deficiency for your child. Many parents describe a journey that includes:

• Grief: Grief for the child you imagined, the milestones that may not come, the future you had pictured. This grief is valid and does not mean you love your child any less. It can coexist with deep love and joy.
• Relief: After years of testing and uncertainty, having a name for your child’s condition can bring a strange sense of relief. You are not imagining things. There is a reason. You can stop searching for the diagnosis and start focusing on living.
• Isolation: With a condition this rare, you may feel profoundly alone. No one in your community, possibly no one in your state, understands what you are going through. This isolation is real and it hurts. Connecting with other rare disease families (even with different diagnoses) can help.
• Advocacy: Many parents channel their energy into advocacy — fighting for services, pushing for research, educating medical professionals, building community. This can be enormously fulfilling and impactful.
• Acceptance: This does not mean giving up or being happy about the diagnosis. It means finding peace with reality as it is, celebrating your child for who they are, and building the best possible life with the cards you have been dealt.
• Joy: Despite everything, joy is not only possible but expected. Your child will make you laugh, surprise you with what they learn, and teach you about resilience, patience, and unconditional love in ways you could never have imagined.

Self-care is not selfish. It is necessary. You cannot pour from an empty cup. Sleep when you can. Accept help. Say no to things that drain you. Protect your marriage or partnership. Move your body. See your own doctor. You are running a marathon, not a sprint. Pace yourself.

• What exact PUS7 mutation does my child have?
• Has this specific mutation been described in other patients, and if so, what were their features?
• Are you willing to learn about PUS7 deficiency with us, given that you may not have seen it before?
• What specialist referrals should we make immediately?
• Should we contact the NIH Undiagnosed Diseases Program?
• Is there a natural history study or patient registry we should join?

• Should our other children be tested for carrier status?
• At what age should carrier testing be offered to siblings?
• What are our options for future pregnancies (prenatal testing, PGT-M)?
• Should extended family members (aunts, uncles, cousins) consider carrier testing?
• Is there a genetic counselor who specializes in rare autosomal recessive conditions?

• Are you aware of any gene therapy research for PUS7 or related tRNA modification disorders?
• Can you help us contact the NIH Bespoke Gene Therapy Consortium?
• Is there a PUS7 mouse model being developed?
• How can we contribute our child’s medical data and samples to research?
• Are there any pharmaceutical companies or academic labs working on epitranscriptomic therapies?

• Does my child need an EEG, and if so, routine or prolonged?
• What type of seizures does my child have?
• What medication do you recommend and what are the side effects in children with intellectual disability?
• Should we have rescue medication at home and at school?
• What should the seizure action plan include?
• How often should seizure medication levels be checked?

• Should we pursue a functional behavior assessment?
• Is ABA therapy appropriate for my child, and how do we find a qualified BCBA?
• At what point should we consider medication for behavioral issues?
• What behavioral medications are safest in children with intellectual disability?
• How do we manage aggression and self-injury safely at home?

• When should we start transition planning?
• Can you recommend adult providers who accept patients with intellectual disability?
• What health screenings should continue into adulthood?
• Should we apply for guardianship, and when?
• What adult services (day programs, supported employment, residential) are available in our area?

While no PUS7-specific therapy is in development, broader epitranscriptomic research is advancing:

• European Union: EU-funded research programs studying RNA modifications in development and disease, including the epitranscriptomics of brain disorders.
• Japan: Active research in tRNA biology and modifications at institutions including RIKEN and University of Tokyo.
• United States: NIH-funded research into tRNA modification enzymes and their roles in neurodevelopment. The BGTC infrastructure exists to translate discoveries into therapies.

• “PUS7 pseudouridine synthase intellectual disability”
• “tRNA modification disorder neurodevelopment”
• “epitranscriptomic intellectual disability”
• “IDDABS OMIM 618342”
• “AAV9 gene therapy intellectual disability”
• “bespoke gene therapy consortium rare disease”
• “pseudouridylation tRNA brain development”
• “PUS1 PUS3 NSUN2 tRNA modification”